Patents Assigned to Hadasit Medical Research Services and Development
  • Safe device for iontophoretic delivery of drugs
    Patent number: 9555238
    Abstract: Provided is a device for iontophoretic delivery of a drug to or into a tissue, including an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. Also provided is a method for iontophorectivally administering drug to or into a tissue, including determining a maximal allowed level of current density and preventing application of current density above the maximal allowed level.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: January 31, 2017
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Abraham J. Domb, Joseph Frucht-Pery, Mervyn Shapiro
  • MIR-122* AS AN ACTIVE MICRO-RNA, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
    Publication number: 20160333344
    Abstract: Provided is a miR-122* as a functional microRNA molecule, compositions including the same and uses thereof for treatment of various conditions, such as, cancer.
    Type: Application
    Filed: January 6, 2015
    Publication date: November 17, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Hilla GILADI, Alina SIMERZIN, Yael HANTZ, Sagit ARBEL ALON, Eithan GALUN
  • IMPROVED CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY
    Publication number: 20160333072
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
  • ALGINATE BIOMATERIALS FOR THE TREATMENT OF HEPATIC DISORDERS
    Publication number: 20160317570
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Application
    Filed: July 10, 2016
    Publication date: November 3, 2016
    Applicants: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron ILAN, Gadi LALAZAR, Eyal SHTEYER, Ami BEN-YA'ACOV, Smadar COHEN, Tsiona ELKAYAM
  • Compositions and methods for amelioration and prevention of drug-induced toxicity
    Patent number: 9474763
    Abstract: Pharmaceutical compositions including combinations of protective agents selected from isosilybin B, methylsulfonylmethane (MSM), phosphatidylcholine, cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N-acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for reducing and/or preventing drug-induced toxicity, such as acetaminophen-induced toxicity. The compositions may be formulated with or without acetaminophen, and accordingly may be used as safe formulations of acetaminophen with reduced risk of causing liver damage, or as an antidote for the treatment of acetaminophen overdose. Methods for treating acetaminophen intoxication.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 25, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Josef Mograbi, Yaron Ilan
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9469855
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: October 18, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • METHOD OF OBTAINING TERMINALLY DIFFERENTIATED NEURONAL LINEAGES AND USES THEREOF
    Publication number: 20160251619
    Abstract: Provided is a method of inducing transdifferentiation of mesenchymal stem cells (MSC), the method including (a) culturing MSC in a first culture medium including a growth factor selected for allowing formation of neuralized MSC (NMSC); (b) allowing the NMSC to proliferate for a sufficient time during which said culture medium is renewed at least once; and (c) culturing the NMSC of (b) in a second culture media including cerebrospinal fluid (CSF) for a time sufficient for the NMSC to differentiate into a population of cells including terminally differentiated neurons, astrocytes and oligodendrocytes. Also provided by the present invention is the use of MSC or NMSC for providing a composition including said population and to kits including MSC or NMSC and instructions for use of same.
    Type: Application
    Filed: October 7, 2014
    Publication date: September 1, 2016
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Dimitrios KARUSSIS, Ibrahim KASSIS
  • ANTI-LPS ENRICHED IMMUNOGLOBULIN FOR USE IN TREATMENT AND/OR PROPHYLAXIS OF FIBROSIS
    Publication number: 20160251414
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Application
    Filed: October 29, 2014
    Publication date: September 1, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • Compositions and methods for treatment of hematological malignancies
    Patent number: 9388230
    Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: July 12, 2016
    Assignees: KAHR MEDICAL(2005) LTD, HADASIT MEDICAL RESEARCH SERVICE AND DEVELOPMENT CO. LTD.
    Inventor: Michal Dranitzki Elhalel
  • Alginate biomaterials for the treatment of hepatic disorders
    Patent number: 9387222
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: July 12, 2016
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam
  • ALLOGENEIC TUMOR CELL VACCINATION
    Publication number: 20160175416
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 23, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar PERETZ, Michal LOTEM, Arthur MACHLENKIN, Shoshana FRANKENBURG, Inna BEN DAVID, Anna KUZNETZ, Yael GELFAND, Galit EISENBERG, Merav DARASH YAHANA
  • Targeting of innate immune response to tumor site
    Patent number: 9358307
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: June 7, 2016
    Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • DEVICES AND METHODS FOR PERCUTANEOUS ENDOSCOPIC GASTROSTOMY AND OTHER OSTOMY PROCEDURES
    Publication number: 20160143816
    Abstract: Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Ishay BENURI-SILBIGER
  • Synthetic analogs of sphingolipids
    Patent number: 9340488
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 17, 2016
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavy
  • METHODS OF OBTAINING CELL POPULATIONS ENRICHED WITH DESIRED CELLS
    Publication number: 20160097032
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona COHEN EVENRAM, Benjamin REUBINOFF
  • Allogeneic tumor cell vaccination
    Patent number: 9301998
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: April 5, 2016
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Assay and kit and device for removing amylase from body fluids
    Patent number: 9297804
    Abstract: The invention is directed to separation of amylase from body fluid by contacting said body fluid with starch under conditions enabling binding between the amylase and the starch, separating between the starch-amylase bound complexes and the free components, thereby removing the bound amylase, and collecting the non-bound components.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: March 29, 2016
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Aaron Palmon, Omer Doitch, Doron Aframian
  • Methods of obtaining cell populations enriched with desired cells
    Patent number: 9243225
    Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: January 26, 2016
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Sharona Cohen Evenram, Benjamin Reubinoff
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9243294
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NLGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 26, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • Molecular imaging agents
    Patent number: 9205156
    Abstract: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: December 8, 2015
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
    Inventors: Eyal Mishani, Ohad Ilovich, Hana Billauer, Sharon Dotan, Haim Danenberg, Moshe Bocher, Galith Abourbeh, Nanette Freedman